Oculis Holding AG (OCS)
NASDAQ: OCS · Real-Time Price · USD
29.93
+0.44 (1.49%)
May 26, 2026, 4:00 PM EDT - Market closed
Oculis Holding AG Revenue
Oculis Holding AG had revenue of 209.00K CHF in the quarter ending March 31, 2026, a decrease of -26.67%. This brings the company's revenue in the last twelve months to 1.12M, up 50.07% year-over-year. In the year 2025, Oculis Holding AG had annual revenue of 1.20M with 74.78% growth.
Revenue (ttm)
1.12M CHF
Revenue Growth
+50.07%
P/S Ratio
1,264.92
Revenue / Employee
18,733 CHF
Employees
60
Market Cap
1.77B USD
Revenue Chart
* This company reports financials in CHF.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.20M | 513.00K | 74.78% |
| Dec 31, 2024 | 686.00K | -197.00K | -22.31% |
| Dec 31, 2023 | 883.00K | -29.00K | -3.18% |
| Dec 31, 2022 | 912.00K | -48.00K | -5.00% |
| Dec 31, 2021 | 960.00K | -33.00K | -3.32% |
| Dec 31, 2020 | 993.00K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sarepta Therapeutics | 2.18B |
| Harmony Biosciences Holdings | 899.11M |
| Vericel | 292.09M |
| AnaptysBio | 232.39M |
| Syndax Pharmaceuticals | 217.17M |
| Nurix Therapeutics | 71.78M |
| Intellia Therapeutics | 66.09M |
| Agios Pharmaceuticals | 66.05M |
OCS News
- 6 days ago - Oculis initiated with a Buy at Guggenheim - TheFly
- 8 days ago - Oculis price target raised to $42 from $38 at JPMorgan - TheFly
- 11 days ago - Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities - GlobeNewsWire
- 12 days ago - Oculis Publishes Results of 2026 Annual General Meeting and Announces Election of Gregory D. Perry to its Board of Directors - GlobeNewsWire
- 13 days ago - Oculis Holding AG Transcript: AGM 2026 - Transcripts
- 13 days ago - Oculis Holding AG Slides: FY 2026 - Filings
- 14 days ago - Oculis price target raised to $47 from $44 at H.C. Wainwright - TheFly
- 14 days ago - Oculis price target raised to $44 from $43 at BofA - TheFly